548 related articles for article (PubMed ID: 19442764)
1. Fluorescent mesoporous silica nanotubes incorporating CdS quantum dots for controlled release of ibuprofen.
Yang YJ; Tao X; Hou Q; Chen JF
Acta Biomater; 2009 Nov; 5(9):3488-96. PubMed ID: 19442764
[TBL] [Abstract][Full Text] [Related]
2. Mesoporous silica nanotubes coated with multilayered polyelectrolytes for pH-controlled drug release.
Yang YJ; Tao X; Hou Q; Ma Y; Chen XL; Chen JF
Acta Biomater; 2010 Aug; 6(8):3092-100. PubMed ID: 20197128
[TBL] [Abstract][Full Text] [Related]
3. Mesoporous silica material TUD-1 as a drug delivery system.
Heikkilä T; Salonen J; Tuura J; Hamdy MS; Mul G; Kumar N; Salmi T; Murzin DY; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
Int J Pharm; 2007 Feb; 331(1):133-8. PubMed ID: 17046183
[TBL] [Abstract][Full Text] [Related]
4. A magnetic, luminescent and mesoporous core-shell structured composite material as drug carrier.
Yang P; Quan Z; Hou Z; Li C; Kang X; Cheng Z; Lin J
Biomaterials; 2009 Sep; 30(27):4786-95. PubMed ID: 19520428
[TBL] [Abstract][Full Text] [Related]
5. Hybrid organic-inorganic silica gel carriers with controlled drug-delivery properties.
Contessotto L; Ghedini E; Pinna F; Signoretto M; Cerrato G; Crocellà V
Chemistry; 2009 Nov; 15(44):12043-9. PubMed ID: 19774561
[TBL] [Abstract][Full Text] [Related]
6. Luminescent porous silica fibers as drug carriers.
Hou Z; Zhang C; Li C; Xu Z; Cheng Z; Li G; Wang W; Peng C; Lin J
Chemistry; 2010 Dec; 16(48):14513-9. PubMed ID: 21077051
[TBL] [Abstract][Full Text] [Related]
7. Luminescence functionalization of SBA-15 by YVO4:Eu3+ as a novel drug delivery system.
Yang P; Huang S; Kong D; Lin J; Fu H
Inorg Chem; 2007 Apr; 46(8):3203-11. PubMed ID: 17371013
[TBL] [Abstract][Full Text] [Related]
8. Luminescence functionalization of mesoporous silica with different morphologies and applications as drug delivery systems.
Yang P; Quan Z; Lu L; Huang S; Lin J
Biomaterials; 2008 Feb; 29(6):692-702. PubMed ID: 17996294
[TBL] [Abstract][Full Text] [Related]
9. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
10. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions.
Song SW; Hidajat K; Kawi S
Langmuir; 2005 Oct; 21(21):9568-75. PubMed ID: 16207037
[TBL] [Abstract][Full Text] [Related]
11. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules.
Lai CY; Trewyn BG; Jeftinija DM; Jeftinija K; Xu S; Jeftinija S; Lin VS
J Am Chem Soc; 2003 Apr; 125(15):4451-9. PubMed ID: 12683815
[TBL] [Abstract][Full Text] [Related]
12. Preparation of luminescent and mesoporous Eu3+/Tb3+ doped calcium silicate microspheres as drug carriers via a template route.
Kang X; Huang S; Yang P; Ma P; Yang D; Lin J
Dalton Trans; 2011 Mar; 40(9):1873-9. PubMed ID: 21183970
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property.
Charnay C; Bégu S; Tourné-Péteilh C; Nicole L; Lerner DA; Devoisselle JM
Eur J Pharm Biopharm; 2004 May; 57(3):533-40. PubMed ID: 15093603
[TBL] [Abstract][Full Text] [Related]
14. Magnetic silica nanotubes: synthesis, drug release, and feasibility for magnetic hyperthermia.
Chen X; Klingeler R; Kath M; El Gendy AA; Cendrowski K; Kalenczuk RJ; Borowiak-Palen E
ACS Appl Mater Interfaces; 2012 Apr; 4(4):2303-9. PubMed ID: 22486255
[TBL] [Abstract][Full Text] [Related]
15. Sol-gel processing of anti-inflammatory entrapment in silica, release kinetics, and bioactivity.
Catauro M; Melisi D; Curcio A; Rimoli MG
J Biomed Mater Res A; 2008 Dec; 87(4):843-9. PubMed ID: 18200553
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, amino-functionalization of mesoporous silica and its adsorption of Cr(VI).
Li J; Miao X; Hao Y; Zhao J; Sun X; Wang L
J Colloid Interface Sci; 2008 Feb; 318(2):309-14. PubMed ID: 18036539
[TBL] [Abstract][Full Text] [Related]
17. Modifying release of poorly soluble active pharmaceutical ingredients with the amine functionalized SBA-16 type mesoporous materials.
Jadach B; Feliczak-Guzik A; Nowak I; Milanowski B; Piotrowska-Kempisty H; Murias M; Lulek J
J Biomater Appl; 2019 Apr; 33(9):1214-1231. PubMed ID: 30791849
[TBL] [Abstract][Full Text] [Related]
18. Amine bridges grafted mesoporous silica, as a prolonged/controlled drug release system for the enhanced therapeutic effect of short life drugs.
Rehman F; Ahmed K; Airoldi C; Gaisford S; Buanz A; Rahim A; Muhammad N; Volpe PLO
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():34-41. PubMed ID: 28024595
[TBL] [Abstract][Full Text] [Related]
19. Potential of amorphous microporous silica for ibuprofen controlled release.
Aerts CA; Verraedt E; Depla A; Follens L; Froyen L; Van Humbeeck J; Augustijns P; Van den Mooter G; Mellaerts R; Martens JA
Int J Pharm; 2010 Sep; 397(1-2):84-91. PubMed ID: 20619331
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous calcium silicate for controlled release of bovine serum albumin protein.
Xue W; Bandyopadhyay A; Bose S
Acta Biomater; 2009 Jun; 5(5):1686-96. PubMed ID: 19249262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
